Sunday - February 1, 2026
Exdensur Approved in Japan for Severe Asthma and Chronic Rhinosinusitis With Nasal Polyps
January 07, 2026
LONDON, England, Jan. 7 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Jan. 6, 2026:

* * *

Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps

* Exdensur is the first and only ultra-long-acting biologic in Japan for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)

* Approval based on data from the SWIFT . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products